<p>DAVENPORT &amp; Co LLC 在第三季度購買了 Cognition Therapeutics, Inc. (NASDAQ:CGTX - 免費報告) 的新股份，根據其最近向 SEC 提交的文件。該基金購買了 2,689,336 股公司股票，價值約為 3,631,000 美元。截至其最近向 SEC 提交的文件，DAVENPORT &amp; Co LLC 擁有 Cognition Therapeutics 約 3.66% 的股份。</p>
<ul>
<li>11 月的小型股珍寶：3 只有望增長的股票</li>
</ul>
<p>另外，Northeast Financial Consultants Inc 在第一季度將其在 Cognition Therapeutics 的股份增加了 158.6%。Northeast Financial Consultants Inc 目前擁有 63,351 股公司股票，價值 27,000 美元，在此期間又購買了 38,851 股。當前 43.35% 的股票由機構投資者持有。</p>
<p>獲取 <strong>Cognition Therapeutics</strong> 的提醒：</p>
<h2>Cognition Therapeutics 股價下跌 0.7%</h2>
<p>Cognition Therapeutics 股票週五開盤價為 1.45 美元。該公司的 50 日移動平均價格為 1.61 美元，200 日移動平均價格為 1.37 美元。Cognition Therapeutics, Inc. 的 12 個月低點為 0.22 美元，12 個月高點為 3.83 美元。該股票的市值為 1.2799 億美元，市盈率為 -3.02，貝塔值為 1.23。</p>
<p>Cognition Therapeutics (NASDAQ:CGTX - 獲取免費報告) 最近於 11 月 6 日發佈了季度財報。該公司報告季度每股收益為（0.06）美元，超出分析師共識預期的（0.07）美元 0.01 美元。整體來看，賣方分析師預測 Cognition Therapeutics, Inc. 本年度將發佈 -0.8 的每股收益。</p>
<h2>華爾街分析師觀點</h2>
<p>幾位股票分析師最近對 CGTX 股票發表了評論。華爾街 Zen 在 11 月 8 日的研究報告中將 Cognition Therapeutics 的評級從 “賣出” 上調至 “持有”。HC Wainwright 在 12 月 4 日的報告中重申了 “買入” 評級，並對 Cognition Therapeutics 的股票設定了 3.00 美元的目標價。Weiss Ratings 在週一的研究報告中重申了對 Cognition Therapeutics 的 “賣出（d-）” 評級。最後，B. Riley 在 11 月 21 日的研究報告中重新發布了 “買入” 評級，並將 Cognition Therapeutics 的目標價從 2.00 美元上調至 3.00 美元。一位研究分析師對該股票給予了強烈買入評級，三位給予了買入評級，一位給予了賣出評級。根據 MarketBeat 的數據，該公司目前的平均評級為 “適度買入”，共識目標價為 3.33 美元。</p>
<p><strong>獲取我們關於 Cognition Therapeutics 的最新研究報告</strong></p>
<h2>Cognition Therapeutics 公司簡介</h2>
<p>（免費報告）</p>
<p>Cognition Therapeutics, Inc 是一家臨牀階段的生物製藥公司，專注於開發針對神經退行性疾病的疾病修正療法，重點關注阿爾茨海默病。該公司的主要研究候選藥物 CT1812 是一種口服小分子，能夠拮抗 sigma-2 受體複合物，以保護突觸免受澱粉樣β寡聚體毒性的影響。通過針對一種新機制，Cognition Therapeutics 旨在減緩或逆轉阿爾茨海默病患者的認知衰退。</p>
<p>CT1812 已成功完成第一階段安全性研究和初步第二階段臨牀試驗，目前正在北美和歐洲對輕度至中度阿爾茨海默病患者進行多項第二階段臨牀研究。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Cognition Therapeutics</li>
<li>請勿刪除，立即閲讀</li>
<li>投資者警報：微型 “$3 AI 奇蹟股票” 即將騰飛</li>
<li>資本利得税是否可以扣除任何費用？</li>
<li>你知道亞馬遜計劃在 1 月 1 日做什麼嗎？</li>
<li>巴菲特、蓋茨和貝索斯悄悄拋售股票——原因在這裏</li>
</ul>
<p><strong>想看看其他對 CGTX 持有的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取 Cognition Therapeutics, Inc. (NASDAQ:CGTX - 免費報告) 的最新 13F 文件和內部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0dUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0dUWA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Cognition Therapeutics 嗎？</h2>
<p>在考慮投資 Cognition Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Cognition Therapeutics 並不在名單上。</p>
<p>雖然 Cognition Therapeutics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

CGTX

<p>DAVENPORT & Co LLC 投資了 Cognition Therapeutics, Inc.，購買了 2,689,336 股，價值 3,631,000 美元，持有該公司 3.66% 的股份。Cognition Therapeutics 的股票開盤價為 1.45 美元，市值為 1.2799 億美元。分析師的評級不一，普遍目標價為 3.33 美元。該公司專注於阿爾茨海默病療法，其主要候選藥物 CT1812 正在進行第二階段臨牀試驗</p>

<p>DAVENPORT &amp; Co LLC purchased a new stake in Cognition Therapeutics, Inc. (NASDAQ:CGTX - Free Report) in the 3rd quarter, according to its most recent filing with the SEC. The fund purchased 2,689,336 shares of the company's stock, valued at approximately $3,631,000. DAVENPORT &amp; Co LLC owned about 3.66% of Cognition Therapeutics as of its most recent filing with the SEC.</p>
<div class="lb-trans"><p>DAVENPORT &amp; Co LLC 在第三季度購買了 Cognition Therapeutics, Inc. (NASDAQ:CGTX - 免費報告) 的新股份，根據其最近向 SEC 提交的文件。該基金購買了 2,689,336 股公司股票，價值約為 3,631,000 美元。截至其最近向 SEC 提交的文件，DAVENPORT &amp; Co LLC 擁有 Cognition Therapeutics 約 3.66% 的股份。</p>
</div><ul>
<li>November’s Small-Cap Treasures: 3 Stocks Poised for Growth</li>
</ul>
<div class="lb-trans"><ul>
<li>11 月的小型股珍寶：3 只有望增長的股票</li>
</ul>
</div><p>Separately, Northeast Financial Consultants Inc grew its position in shares of Cognition Therapeutics by 158.6% in the first quarter. Northeast Financial Consultants Inc now owns 63,351 shares of the company's stock valued at $27,000 after purchasing an additional 38,851 shares during the period. 43.35% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>另外，Northeast Financial Consultants Inc 在第一季度將其在 Cognition Therapeutics 的股份增加了 158.6%。Northeast Financial Consultants Inc 目前擁有 63,351 股公司股票，價值 27,000 美元，在此期間又購買了 38,851 股。當前 43.35% 的股票由機構投資者持有。</p>
</div><p>Get <strong>Cognition Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Cognition Therapeutics</strong> 的提醒：</p>
</div><h2>Cognition Therapeutics Trading Down 0.7%</h2>
<div class="lb-trans"><h2>Cognition Therapeutics 股價下跌 0.7%</h2>
</div><p>Shares of Cognition Therapeutics stock opened at $1.45 on Friday. The business's fifty day moving average price is $1.61 and its 200 day moving average price is $1.37. Cognition Therapeutics, Inc. has a twelve month low of $0.22 and a twelve month high of $3.83. The stock has a market capitalization of $127.99 million, a P/E ratio of -3.02 and a beta of 1.23.</p>
<div class="lb-trans"><p>Cognition Therapeutics 股票週五開盤價為 1.45 美元。該公司的 50 日移動平均價格為 1.61 美元，200 日移動平均價格為 1.37 美元。Cognition Therapeutics, Inc. 的 12 個月低點為 0.22 美元，12 個月高點為 3.83 美元。該股票的市值為 1.2799 億美元，市盈率為 -3.02，貝塔值為 1.23。</p>
</div><p>Cognition Therapeutics (NASDAQ:CGTX - Get Free Report) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. As a group, sell-side analysts predict that Cognition Therapeutics, Inc. will post -0.8 EPS for the current year.</p>
<div class="lb-trans"><p>Cognition Therapeutics (NASDAQ:CGTX - 獲取免費報告) 最近於 11 月 6 日發佈了季度財報。該公司報告季度每股收益為（0.06）美元，超出分析師共識預期的（0.07）美元 0.01 美元。整體來看，賣方分析師預測 Cognition Therapeutics, Inc. 本年度將發佈 -0.8 的每股收益。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>Several equities analysts recently commented on CGTX shares. Wall Street Zen upgraded Cognition Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, November 8th. HC Wainwright restated a &#34;buy&#34; rating and issued a $3.00 price target on shares of Cognition Therapeutics in a report on Thursday, December 4th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Cognition Therapeutics in a research note on Monday. Finally, B. Riley reissued a &#34;buy&#34; rating and issued a $3.00 target price (up from $2.00) on shares of Cognition Therapeutics in a research report on Friday, November 21st. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $3.33.</p>
<div class="lb-trans"><p>幾位股票分析師最近對 CGTX 股票發表了評論。華爾街 Zen 在 11 月 8 日的研究報告中將 Cognition Therapeutics 的評級從 “賣出” 上調至 “持有”。HC Wainwright 在 12 月 4 日的報告中重申了 “買入” 評級，並對 Cognition Therapeutics 的股票設定了 3.00 美元的目標價。Weiss Ratings 在週一的研究報告中重申了對 Cognition Therapeutics 的 “賣出（d-）” 評級。最後，B. Riley 在 11 月 21 日的研究報告中重新發布了 “買入” 評級，並將 Cognition Therapeutics 的目標價從 2.00 美元上調至 3.00 美元。一位研究分析師對該股票給予了強烈買入評級，三位給予了買入評級，一位給予了賣出評級。根據 MarketBeat 的數據，該公司目前的平均評級為 “適度買入”，共識目標價為 3.33 美元。</p>
</div><p><strong>Get Our Latest Research Report on Cognition Therapeutics</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 Cognition Therapeutics 的最新研究報告</strong></p>
</div><h2>Cognition Therapeutics Profile</h2>
<div class="lb-trans"><h2>Cognition Therapeutics 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Cognition Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders, with an emphasis on Alzheimer's disease. The company's lead investigational candidate, CT1812, is an oral small molecule that antagonizes the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. By targeting a novel mechanism of action, Cognition Therapeutics aims to slow or reverse cognitive decline in patients living with Alzheimer's disease.</p>
<div class="lb-trans"><p>Cognition Therapeutics, Inc 是一家臨牀階段的生物製藥公司，專注於開發針對神經退行性疾病的疾病修正療法，重點關注阿爾茨海默病。該公司的主要研究候選藥物 CT1812 是一種口服小分子，能夠拮抗 sigma-2 受體複合物，以保護突觸免受澱粉樣β寡聚體毒性的影響。通過針對一種新機制，Cognition Therapeutics 旨在減緩或逆轉阿爾茨海默病患者的認知衰退。</p>
</div><p>CT1812 has successfully completed Phase 1 safety studies and preliminary Phase 2a trials, and is currently being evaluated in multiple Phase 2 clinical studies across North America and Europe in patients with mild-to-moderate Alzheimer's disease.</p>
<div class="lb-trans"><p>CT1812 已成功完成第一階段安全性研究和初步第二階段臨牀試驗，目前正在北美和歐洲對輕度至中度阿爾茨海默病患者進行多項第二階段臨牀研究。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Cognition Therapeutics</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>Do you know what Amazon is planning for January 1?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Cognition Therapeutics</li>
<li>請勿刪除，立即閲讀</li>
<li>投資者警報：微型 “$3 AI 奇蹟股票” 即將騰飛</li>
<li>資本利得税是否可以扣除任何費用？</li>
<li>你知道亞馬遜計劃在 1 月 1 日做什麼嗎？</li>
<li>巴菲特、蓋茨和貝索斯悄悄拋售股票——原因在這裏</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding CGTX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cognition Therapeutics, Inc. (NASDAQ:CGTX - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對 CGTX 持有的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取 Cognition Therapeutics, Inc. (NASDAQ:CGTX - 免費報告) 的最新 13F 文件和內部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0dUWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=CGTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Cognition Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Cognition Therapeutics 嗎？</h2>
</div><p>Before you consider Cognition Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資 Cognition Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cognition Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Cognition Therapeutics 並不在名單上。</p>
</div><p>While Cognition Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Cognition Therapeutics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

DAVENPORT & Co LLC 對 Cognition Therapeutics, Inc. $CGTX 進行了新的投資